Diagnostic Approach and Treatment for Gonorrhea and Chlamydia

Diagnostic Testing

The Centers for Disease Control and Prevention recommends using nucleic acid amplification tests (NAATs) as the primary diagnostic method for detecting gonorrhea and chlamydia infections, due to their high sensitivity and specificity 1
For women, vaginal swabs (self-collected or clinician-collected) or urine specimens are recommended as first-line specimen options for NAATs 1, 3
For men, first-void urine or urethral swabs are recommended as first-line specimen options for NAATs 4, 5
NAATs are preferred due to their high sensitivity (86-100%) and specificity (>97%) for both infections 6
The same specimen can be used to test for both chlamydia and gonorrhea simultaneously 1

The American College of Physicians recommends annual screening for all sexually active females ≤24 years old 7
Females >24 years with risk factors, such as new or multiple sex partners, should be screened for chlamydia and gonorrhea 1

The Centers for Disease Control and Prevention recommends against using fluoroquinolones like ciprofloxacin and ofloxacin for gonorrhea treatment without confirmed susceptibility due to increasing resistance 2
Antimicrobial resistance monitoring is essential as resistance patterns continue to evolve 2
For pregnant patients, azithromycin is preferred for chlamydia treatment due to its safety profile 4

Patients with gonorrhea should receive treatment effective against both gonorrhea and chlamydia due to frequent co-infection 2
If chlamydia test results are not available or if a non-NAAT was negative for chlamydia, treat for both infections 2

The Centers for Disease Control and Prevention recommends retesting all patients diagnosed with chlamydia or gonorrhea approximately 3 months after treatment due to high reinfection rates 1
All sex partners from the preceding 60 days should be evaluated, tested, and treated 1
Patients should abstain from sexual intercourse until they and their partners have completed treatment and are asymptomatic 1

Diagnostic errors can occur if Gram stain is relied upon for endocervical, pharyngeal, or rectal specimens, as they lack sufficient sensitivity 2
Treatment failures can occur if quinolones are used for gonorrhea treatment without confirmed susceptibility due to increasing resistance 2
Inadequate follow-up can lead to missed reinfections if patients are not retested after 3 months 1
Missed co-infections can occur if patients are not tested for other STIs when testing for gonorrhea or chlamydia 2